Gibson Christopher Insider Trading Activity
Gibson Christopher has been net-selling over the last 12 months with 0 purchases and 21 sales across 1 company.
RXRX is the most-traded position with 21 trades. The largest single transaction was a sale of RXRX for $2.6M on Aug 11, 2025.
Performance Scorecard
Forward stock performance after each transaction by Gibson Christopher. Buy returns measure price movement after open-market purchases; sell-avoided measures the loss avoided after open-market sales. Success rate counts trades where the insider's direction was right.
| PERIOD | AVG BUY RETURN | AVG SELL AVOIDED | SUCCESS RATE | TRADES |
|---|---|---|---|---|
| 30 days | — | +4.6% | 71% | 21 |
| 90 days | — | +13.2% | 89% | 19 |
| 120 days | — | +16.9% | 100% | 17 |
Performance based on stock price movement after each transaction date. Past results do not predict future returns. Not financial advice.
Price & Trades
Pro: Trade MarkersRXRX · RECURSION PHARMACEUTICALS, INC.
🔒 Subscribe to see trade entries
Pro members see exactly when Gibson Christopher bought and sold RXRX.
Upgrade to ProRecent Trades
| DATE | TICKER | TYPE | SHARES | PRICE | VALUE | Δ OWNED | ROLE | FILING |
|---|---|---|---|---|---|---|---|---|
Jun 5, 2026 | RXRX | Sell | 40,000 | $3.62 | $145K | −4.3% | Director | |
May 7, 2026 | RXRX | Sell | 40,000 | $3.37 | $135K | −4.1% | Director | |
Apr 22, 2026 | RXRX | Sell | 40,000 | $3.61 | $144K | −4.2% | Director | |
Apr 7, 2026 | RXRX | Sell | 40,000 | $3.10 | $124K | −4.2% | Director | |
Mar 23, 2026 | RXRX | Sell | 40,000 | $3.25 | $130K | −4.2% | Director | |
Feb 19, 2026 | RXRX | Sell | 40,000 | $3.46 | $138K | −4.2% | Director | |
Feb 4, 2026 | RXRX | Sell | 40,000 | $4.12 | $165K | −4.2% | Director | |
Jan 20, 2026 | RXRX | Sell | 40,000 | $4.47 | $179K | −4.2% | Director | |
Jan 5, 2026 | RXRX | Sell | 40,000 | $4.25 | $170K | −4.1% | Director | |
Dec 19, 2025 | RXRX | Sell | 40,000 | $4.50 | $180K | −4.2% | CEO | |
Dec 4, 2025 | RXRX | Sell | 40,000 | $4.63 | $185K | −4.1% | CEO | |
Nov 19, 2025 | RXRX | Sell | 40,000 | $4.16 | $166K | −4.2% | CEO | |
Nov 4, 2025 | RXRX | Sell | 40,000 | $5.21 | $208K | −3.9% | CEO | |
Oct 23, 2025 | RXRX | Sell | 100,000 | $5.70 | $570K | −9.5% | CEO | |
Oct 10, 2025 | RXRX | Sell | 100,000 | $6.04 | $604K | −9.3% | CEO | |
Sep 25, 2025 | RXRX | Sell | 100,000 | $4.76 | $476K | −9.5% | CEO | |
Sep 10, 2025 | RXRX | Sell | 100,000 | $4.71 | $471K | −9.3% | CEO | |
Aug 26, 2025 | RXRX | Sell | 100,000 | $4.84 | $484K | −9.5% | CEO | |
Aug 11, 2025 | RXRX | Sell | 500,300 | $5.28 | $2.6M | −33.2% | CEO | |
Aug 11, 2025 | RXRX | Sell | 100,000 | $5.28 | $528K | −100.0% | CEO | |
Aug 11, 2025 | RXRX | Sell | 17,875 | $5.28 | $94K | −100.0% | CEO |
Top Companies Traded
| TICKER | COMPANY | TRADES | TOTAL VOLUME |
|---|---|---|---|
| RXRX | RECURSION PHARMACEUTICALS, INC. | 21 | $7.9M |
Other insiders at RECURSION PHARMACEUTICALS, INC.
3 other tracked filers at RXRX.